{"id":"W4386631299","doi":"10.1016/s1470-2045(23)00382-0","title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; Janssen Pharmaceuticals; Invitae; Gilead Sciences; Merck; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ipsen; BeiGene; Constellation Pharmaceuticals","keywords":"Abiraterone; Prostate cancer; Medicine; Placebo; Olaparib; Urology; Abiraterone acetate; Internal medicine; Oncology; Double blind; Androgen deprivation therapy; Cancer; Androgen receptor; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002159244,0.002361138,0.003331904,0.0006105903,0.0005144275,0.00159724,0.001113283,0.001863388,0.007873175],"category_scores_gemma":[0.002771212,0.0007547368,0.00278788,0.0005263145,0.001507529,0.001602237,0.0005491653,0.003746501,0.001431625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008219254,"about_ca_system_score_gemma":0.001247324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001193887,"about_ca_topic_score_gemma":0.002541417,"domain_scores_codex":[0.9991913,0.0004771814,0.00004720259,0.0001237555,0.00005251837,0.0001080188],"domain_scores_gemma":[0.9984567,0.0006609614,0.0003000228,0.0001276827,0.00006884808,0.0003857503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9884332,0.001053778,0.0001051804,0.0004020201,0.0005382941,0.00001686659,0.00003207723,0.0002385435,0.0007605168,0.00006017259,0.0003552637,0.008004147],"study_design_scores_gemma":[0.9758005,0.02268901,0.0003922287,0.00002740501,0.0002621965,0.00001945305,0.00001508897,0.0001973689,0.0001593197,0.0001706197,0.0002535817,0.00001313399],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762135,0.01091142,0.001361222,0.001383428,0.001325108,0.002932262,0.001919389,0.0004584317,0.003495322],"genre_scores_gemma":[0.9823423,0.004565611,0.001801509,0.001279584,0.0007393404,0.002568159,0.001279523,0.0000699616,0.005353998],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007873175,"threshold_uncertainty_score":0.0263384,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.313893449351758,"score_gpt":0.459480059444977,"score_spread":0.145586610093219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}